Inoviq Ltd Unveils Groundbreaking Early Ovarian Cancer Screening Data at ASCO, Shares Surge 35%

Key Highlights:

• Inoviq’s EXO-OC™ test shows 77% sensitivity at 99.6% specificity for ovarian cancer detection.
• The test accurately identifies all early-stage (I and II) ovarian cancers—no missed diagnoses.
• New provisional patent filed to protect the technology’s IP.
• Shares soar 35.23% to $0.595; 1-year return stands at +27.96%.
• Market cap at $66.4 million, with 111.63 million shares on issue.

Inoviq Ltd (ASX: IIQ) has captured the market’s attention with a major scientific milestone, unveiling data from its EXO-OC™ ovarian cancer screening test at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 in Chicago. The test demonstrated 77% sensitivity and an exceptional 99.6% specificity for detecting ovarian cancer across all stages, including flawless detection of early-stage cancers. The news sent Inoviq shares soaring 35.23% to $0.595, marking a remarkable 1-year return of +27.96%.

For a disease notorious for its stealth—ovarian cancer often lacks symptoms until advanced stages—Inoviq’s breakthrough could be a game-changer. The current five-year survival rate for ovarian cancer hovers around 49%, but early detection can dramatically improve outcomes, potentially lifting survival rates to 93%.

The EXO-OC™ test uses a proprietary AI-enhanced algorithm that combines multiple exosomal biomarkers—tiny vesicles secreted by cells, including tumours. The technology was developed in collaboration with leading computational scientist Prof. Amanda Barnard and is powered by Inoviq’s patented EXO-NET® platform. The fully automated test can process over 500 samples daily in a clinical lab setting, offering scalability for widespread use.

Dr. Leearne Hinch, CEO of Inoviq, described the development as a “critical leap forward” for women’s health, noting the test’s potential as a first-in-class screening solution for asymptomatic, average-risk women. With no current screening test for ovarian cancer, the stakes are high, and Inoviq has already filed a new provisional patent to protect the intellectual property behind its biomarker panels and testing methods.

In the near term, Inoviq plans to advance the test through further validation studies, clinical trials, and regulatory pathways—including a targeted Breakthrough Device Designation with the FDA. The commercialisation strategy includes launching the test as a Laboratory Developed Test (LDT) in the US before pursuing full regulatory approval as an In Vitro Diagnostic.

Inoviq’s progress solidifies its positioning as a pioneer in exosome-based diagnostics and therapeutics. With a market cap of $66.4 million and shares up nearly 28% over the past year, investors will be closely watching the company’s next steps—particularly as it aims to deliver a much-needed solution to one of the most lethal gynaecological cancers worldwide.